Clinical relevance of PD-L2 expression in surgically resected lung adenocarcinoma

Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N. Engl. J. Med., 379, 2342, 10.1056/NEJMoa1809697 Borghaei, 2015, Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer, N. Engl. J. Med., 373, 1627, 10.1056/NEJMoa1507643 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 Fehrenbacher, 2016, POPLAR Study Group, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, Lancet, 387, 1837, 10.1016/S0140-6736(16)00587-0 Garon, 2015, Pembrolizumab for the treatment of non–small-cell lung cancer, N. Engl. J. Med., 372, 2018, 10.1056/NEJMoa1501824 Chen, 2012, Molecular pathways: next-generation immunotherapy–inhibiting programmed death-ligand 1 and programmed death-1, Clin. Cancer Res., 18, 6580, 10.1158/1078-0432.CCR-12-1362 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 Takamochi, 2021, Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma, Lung Cancer., 161, 163, 10.1016/j.lungcan.2021.09.011 Zhang, 2017, PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis, Sci. Rep., 7, 10255, 10.1038/s41598-017-10925-7 Chen, 2020, Prognostic implications of programmed death ligand 1 expression in resected lung adenocarcinoma: a systematic review and meta-analysis, Eur. J. Cardiothorac. Surg., 58, 888, 10.1093/ejcts/ezaa172 Rozali, 2012, Programmed death ligand 2 in cancer-induced immune suppression, Clin. Dev. Immunol., 2012, 1, 10.1155/2012/656340 Solinas, 2020, Programmed cell death-ligand 2: a neglected but important target in the immune response to cancer?, Transl. Oncol., 13, 100811, 10.1016/j.tranon.2020.100811 Shinchi, 2019, Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: a retrospective study by double immunohistochemistry, Cancer Sci., 110, 2711, 10.1111/cas.14128 Takamori, 2019, Prognostic impact of programmed death-ligand 2 expression in primary lung adenocarcinoma patients, Ann. Surg. Oncol., 26, 1916, 10.1245/s10434-019-07231-z Zhang, 2014, Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma, Onco. Targets. Ther., 7, 567, 10.2147/OTT.S59959 Yang, 2019, Correlation between PD-L2 expression and clinical outcome in solid cancer patients: a meta-analysis, Front. Oncol., 9, 47, 10.3389/fonc.2019.00047 International Agency for Research on Cancer, 2015 Takamochi, 2016, Novel biomarkers that assist in accurate discrimination of squamous cell carcinoma from adenocarcinoma of the lung, BMC Cancer, 16, 760, 10.1186/s12885-016-2792-1 Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu. Rev. Immunol., 26, 677, 10.1146/annurev.immunol.26.021607.090331 Tanegashima, 2019, Immune suppression by PD-L2 against spontaneous and treatment-related antitumor immunity, Clin. Cancer Res., 25, 4808, 10.1158/1078-0432.CCR-18-3991 Duan, 2020, Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis: a systematic review and meta-analysis, JAMA Oncol., 6, 375, 10.1001/jamaoncol.2019.5367 Cascone, 2021, Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, Nat. Med., 27, 504, 10.1038/s41591-020-01224-2 Forde, 2018, Neoadjuvant PD-1 blockade in resectable lung cancer, N. Engl. J. Med., 378, 1976, 10.1056/NEJMoa1716078 Provencio, 2020, Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial, Lancet Oncol., 21, 1413, 10.1016/S1470-2045(20)30453-8 Shu, 2020, Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial, Lancet Oncol., 21, 786, 10.1016/S1470-2045(20)30140-6 Felip, 2021, IMpower010 Investigators, Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial, Lancet, 398, 1344, 10.1016/S0140-6736(21)02098-5